Advertisement

Topics

GeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update / Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer

09:01 EDT 7 Aug 2017 | FinanzNachrichten

ATLANTA, GA -- (Marketwired) -- 08/07/17 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel viral vector platform technology, announced its finan...

Original Article: GeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update / Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer

NEXT ARTICLE

More From BioPortfolio on "GeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update / Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...